| Synonym |
| Thai / English name |
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : Ginkgo biloba extract*Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Ginkgo biloba extract 25, 50, 100, 200, or 300 mcg/mLDuration : MCF-10A cells were treated with G. biloba extract once every 24 h for 48 h.Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Result: G. biloba extract, at each of the concentrations tested, increased CYP1B1 and CYP1A1 mRNA expression. The extent of induction by G. biloba extract was greater for CYP1A1 than for CYP1B1.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : Ginkgo biloba extract*Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Ginkgo biloba extract 300 mcg/mLDuration : MCF-10A cells were treated with G. biloba extract for 6, 24, or 48 h.Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Result: Treatment of MCF-10A cells with G. biloba extract of 6 h did not affect CYP1B1 mRNA expression, whereas treatment for 24 h and 48 h increased CYP1B1 mRNA levels by 3.4-fold and 4.2-fold, respectively. A similar time profile was obtained for the increase in CYP1A1 mRNA expression by G. biloba extract. The 6 h treatment did not alter CYP1A1 mRNA levels, whereas the 24 and 48 h treatment increased it by 43-fold and 52-fold, respectively.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : Ginkgo biloba extract*Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Ginkgo biloba extract 100 mcg/mLDuration : MCF-10A cells were treated with G. biloba extract and 3',4'-dimethoxyflavone (DMF; an antagonist of AhR) at 1, 5, and 10 mmol/L once every 24 h for 48 h.Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Result: MCF-10A cells were treated with the extract and 3',4'-dimethoxyflavone (DMF; an antagonist of AhR) at 1, 5, and 10 mmol/L decreased CYP1B1 mRNA expression by 45%, 68%, and 79%, respectively. By comparsion, 1, 5, and 10 mmol/L of the AhR antagonist decreased CYP1A1 mRNA expression by 57%, 91%, and 95%, respectively.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : bilobalideType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : bilobalide 2.8 mcg/mLDuration : MCF-10A cells were treated with bilobalide for 24 hType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Result: None of the terpene trilactones increased CYP1B1 or CYP1A1 mRNA expression. These compounds also and had no effect on AhR dependent report activity.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : ginkgolide AType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : ginkgolide A 1.1 mcg/mLDuration : MCF-10A cells were treated with ginkgolide A for 24 hType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Result: None of the terpene trilactones increased CYP1B1 or CYP1A1 mRNA expression. These compounds also and had no effect on AhR dependent report activity.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : ginkgolide BType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : ginkgolide B 0.3 mcg/mLDuration : MCF-10A cells were treated with ginkgolide B for 24 hType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Result: None of the terpene trilactones increased CYP1B1 or CYP1A1 mRNA expression. These compounds also and had no effect on AhR dependent report activity.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : ginkgolide CType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : ginkgolide C 1.4 mcg/mLDuration : MCF-10A cells were treated with ginkgolide C for 24 hType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Result: None of the terpene trilactones increased CYP1B1 or CYP1A1 mRNA expression. These compounds also and had no effect on AhR dependent report activity.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : ginkgolide JType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : ginkgolide J 0.6 mcg/mLDuration : MCF-10A cells were treated with ginkgolide J for 24 hType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Result: None of the terpene trilactones increased CYP1B1 or CYP1A1 mRNA expression. These compounds also and had no effect on AhR dependent report activity.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : isorhamnetin-3-O-rutinosideType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : MCF-10A cells were treated with isorhamnetin-3-O-rutinoside for 24 hType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Result: Treatment of MCF-10A cells with isorhamnetin-3-O-rutinoside did not alter CYP1B1 or CYP1A1 mRNA levels.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : QuercetinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : quercetin 10.6 mcg/mLDuration : MCF-10A cells were treated with quercetin for 48 hType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Result: Quercetin increased CYP1B1 and CYP1A1 mRNA levels by 4-fold and 182-fold, respectively.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
